title: [Clinical trial on the effects of shikonin mixture on later stage lung cancer].
abstract: The shikonin mixture was used for 19 cases of later-stage lung cancer who were not the candidates for operation, radiotherapy and chemotherapy. The clinical observation showed that shikonin mixture could inhibit the growth of lung cancer and improve the immune function of the body. The tumors were reduced over 25% in diameter. The effective rate was 63.3%, remission rate 36.9%, survival rate of one year 47.3%. The intermedium survival period was about 10 months, including adenocarcinoma 10 months, squamous carcinoma 12 months. After treatment the life quality of patients were greatly improved. The patients got better appetite and their body weights were increased. They could manage themselves in daily life. The Karnofsky scores were enhanced by 20. The authors also observed that shikonin mixture could relieve such symptoms as cough, bloody sputum and chest pain caused by lung cancer. The levels of cells and interleukin-2 were increased (P less than 0.001). It had no harmful effects on peripheral blood picture, heart, kidney and liver. Shikonin mixture is safe and effective for later-stage cancer.
authors.affiliation: 2nd Teaching Hospital, Bethune University of Medical Sciences, Changhun.
authors.forename: X P
authors.initials: XP
authors.lastname: Guo
authors.forename: X Y
authors.initials: XY
authors.lastname: Zhang
authors.forename: S D
authors.initials: SD
authors.lastname: Zhang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy* / Q000276:immunology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D005260:Female; D036145:Ginsenosides; D006801:Humans; D007376:Interleukin-2 / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009285:Naphthoquinones / Q000627:therapeutic use*; D012503:Saponins / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D036145:Ginsenosides; D007376:Interleukin-2; D009285:Naphthoquinones; D012503:Saponins; C016101:shikonin